PDX Xenograft Models

Patient-derived xenograft models are established by engrafting tumor tissue taken directly from a patient into an immunodeficient host, with no intervening period of long-term cell culture. The omission of that culture step defines the platform. Established cell lines maintained indefinitely in vitro undergo progressive clonal selection and transcriptional divergence and lose their stromal and immune context. Tissue engrafted directly retains donor histology, copy number landscape, driver mutation profile, and much of the intratumoral heterogeneity present in the original lesion.

Altogen Labs provides PDX model establishment, expansion, and efficacy testing, together with the orthotopic, subrenal capsule, and humanized configurations that extend the platform to specific translational questions. Studies are conducted in an IACUC-regulated facility, and company scientists have published on patient-derived model selection, engraftment biology, and the reporting standards that govern how these models should be documented.

PDX is the appropriate platform where the question concerns donor heterogeneity, preserved tumor architecture, biomarker validation, or resistance biology. Where the question is target dependency, dose-schedule optimization, or rapid proof of mechanism, cell line derived xenografts answer it faster and at lower cost.

Tumor source and tissue handling

Viable tumor material is obtained most commonly from surgical resection, and also from core biopsy, malignant effusions, or marrow aspirates in hematologic disease. Radical resection yields larger volumes of architecturally intact tissue, while directed biopsies provide adequate material particularly from metastatic or unresectable disease.

Handling between the operating room and implantation is a principal determinant of success, and is where patient-derived programs most often fail before they begin. Tissue is transported in cold buffered medium and processed promptly. Prolonged warm ischemia and extended intervals outside the body progressively reduce engraftment efficiency, and material that has been held too long will not establish regardless of how carefully it is implanted afterward. Institutional review board approval and written informed consent are mandatory for all patient-derived material, and provenance documentation is maintained from receipt onward.

To discuss tissue logistics and establishment planning, request a quote.

Implantation and site selection

Tumor material is processed either into small fragments, which preserves extracellular matrix architecture and spatial heterogeneity, or into single cell suspensions where sorting or dose-normalized inoculation is required. Matrigel co-implantation is frequently used to support early vascularization; its effect varies by tumor type and it alters the microenvironmental context, so its use is recorded in the study record rather than applied silently. Hormone supplementation improves engraftment of hormone-dependent disease, with estradiol used for estrogen receptor positive breast tumors and dihydrotestosterone for prostate tumors.

Implantation site determines which questions the model can answer. Subcutaneous flank implantation offers caliper monitoring and operational simplicity. Orthotopic implantation restores the organ-specific microenvironment and supports spontaneous metastasis. Subrenal capsule implantation exploits a densely vascularized site and improves establishment for tumor types that engraft poorly elsewhere.

Engraftment biology

Engraftment is strongly tumor dependent, and this shapes program planning more than any other variable. Aggressive, poorly differentiated, treatment-resistant, and metastatic tumors establish more readily than indolent or well-differentiated disease. Triple negative breast cancer, pancreatic ductal adenocarcinoma, high grade serous ovarian cancer, and acute leukemias establish consistently, while luminal A breast tumors and other indolent entities do not. Successful engraftment is itself prognostic in several indications, since the biological features that permit a tumor to grow in a mouse are the same features associated with poorer patient outcome.

Host background is the second determinant. Severely immunodeficient strains lacking functional natural killer cells have largely displaced nude and SCID hosts for difficult or hematologic cases. Host selection for each program follows the tumor type, the required study duration, and whether an immune compartment is needed.

Passage nomenclature and biological drift

By convention the initial patient implantation is designated F0, with serial passages labeled F1, F2 and onward. Growth kinetics typically stabilize after the earliest passages, and most programs reserve formal pharmacology for F2 or F3 material in order to reduce inter-animal variability. Early passage is commonly defined as F2 through F4, and material beyond F5 carries an increasing risk of subclonal outgrowth and transcriptional drift at a rate that is tumor-type dependent.

Human stroma is progressively replaced by murine stroma across serial passage, and mouse-specific tumor evolution occurs alongside it. Some apparent discordance between a model and its donor reflects subclonal sampling of a spatially heterogeneous tumor rather than model-induced drift. Two practical consequences follow: a PDX model should be characterized longitudinally rather than assumed static, and sequencing, histopathology, and treatment response should be integrated where model selection carries significant downstream consequences.

Applied examples

Biomarker validation. A panel of colorectal PDX models stratified by mutation status is treated with an anti-EGFR agent, establishing whether response tracks with the candidate biomarker across models rather than within a single line.

Co-clinical design. A model established from a patient entering a clinical trial is treated with the same regimen the patient receives, so that model and patient response can be compared directly and the model used to test alternatives the patient cannot.

Resistance characterization. Tumor tissue from a patient who progressed on a targeted agent is engrafted directly, producing a resistance model carrying the escape biology that arose clinically, which is then used to test next-line candidates.

Platforms

Patient-derived orthotopic xenograft models place tissue at the anatomically matched primary site. Subrenal capsule PDX models address difficult-to-engraft tumor types. Humanized PDX models add a human immune compartment for immuno-oncology work. Organoid-derived xenografts permit ex vivo expansion and screening before engraftment. Treatment resistance and relapse models are derived under therapeutic pressure.

Model documentation and reproducibility

A patient-derived model is only reusable if it is documented. Altogen Labs records tumor source, clinical annotation where supplied, host background, implantation site, passage number, and engraftment outcome for every model, consistent with established minimal information reporting standards for patient-derived xenografts. Tumor volume formula, response thresholds, censoring rules, and the analysis plan are specified in the protocol before initiation, since inconsistent growth metrics are a recognized barrier to comparing results between studies. All procedures are conducted under active IACUC protocols, and GLP standards are applied where a study is formally designated as GLP.

Send indication, tissue availability, and study objectives, or request a quote.